sur BioNxt Solutions Inc. (isin : CA0909741062)
BioNxt Solutions Expands Patent Portfolio for Drug Delivery Innovations
BioNxt Solutions Inc., a leader in bioscience, has expanded its intellectual property portfolio with new international patents. These patents focus on sublingual delivery technologies for autoimmune neurodegenerative diseases. This development follows a positive International Preliminary Report on Patentability from the European Patent Office in September 2024.
The company has initiated patent filings in the United States, Canada, Europe, and Japan. These patents aim to protect BioNxt's proprietary sublingual formulations for anticancer drugs, repurposed for conditions like Multiple Sclerosis (MS). BioNxt's leading product, BNT23001, demonstrates promising absorption rates and plans for clinical trials in 2025.
The company has outlined key objectives for 2025, including launching clinical trials, preparing regulatory submissions, and fostering partnerships. BioNxt is also exploring pipeline expansion and industry engagement to advance its sublingual drug delivery platform.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioNxt Solutions Inc.